NiKem Research Srl Enters Into Research Service Agreement with InterMune, Inc.
NiKem Research Srl, an Italian drug discovery service provider, announced that it has entered into a Research Service Agreement with InterMune, Inc. Under the terms of the agreement, NiKem will, in the next 12 months, use its medicinal chemistry and early ADMET/PK platform and expertise to design, synthesize and profile drug-like compounds aimed towards specific, undisclosed pulmonology targets of interest for InterMune. Financial terms of the agreement were not disclosed.
According to the company, by pursuing this business opportunity with InterMune, NiKem Research further diversifies its client portfolio in Europe, the United States and Australia, now comprising large pharmaceutical corporations, small biotechs and a number of medium-sized companies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Cholera bacteria form aggressive biofilm to kill immune cells - The study provides new insights into the infection strategies of pathogens
LifeSpan BioSciences to release 20,000 immunohistochemistry-validated reagent antibodies - Leader in antibody evaluation and validation expands focus to include development and sales of antibodies validated for use in immunohistochemistry

Could insulin come in a pill? - How a molecule that mimics insulin may advance diabetes research

Biomass production by reverse citric acid cycle - Central metabolic pathway runs "backwards" at high carbon dioxide concentrations
